• SPX
  • $5,708.75
  • -0.93 %
  • -$53.73
  • DJI
  • $42,156.97
  • -0.41 %
  • -$173.18
  • N225
  • $37,808.76
  • -2.18 %
  • -$843.21
  • FTSE
  • $8,273.51
  • -0.04 %
  • -$3.14
  • IXIC
  • $17,910.36
  • -1.53 %
  • -$278.81
Allakos Inc. (ALLK) Stock Price, News & Analysis

Allakos Inc. (ALLK) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.62

-$0.03

(-4.6%)

Day's range
$0.62
Day's range
$0.71
50-day range
$0.535
Day's range
$0.96
  • Country: US
  • ISIN: US01671P1003
52 wk range
$0.54
Day's range
$3.41
  • CEO: Dr. Robert Alexander Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -13.60
  • Piotroski Score 3.00
  • Grade Market Outperform
  • Symbol (ALLK)
  • Company Allakos Inc.
  • Price $0.62
  • Changes Percentage (-4.6%)
  • Change -$0.03
  • Day Low $0.62
  • Day High $0.71
  • Year High $3.41

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/11/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $109.50
  • High Stock Price Target $218.00
  • Low Stock Price Target $1.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.46
  • Trailing P/E Ratio -0.47
  • Forward P/E Ratio -0.47
  • P/E Growth -0.47
  • Net Income $-185,701,000

Income Statement

Quarterly

Annual

Latest News of ALLK

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

  • Can Allakos (NASDAQ:ALLK) Afford To Invest In Growth?

    Investors are often attracted to unprofitable companies that show potential for growth, like Salesforce.com. However, these companies carry risks due to cash burn. Allakos' cash burn rate and cash res...

    By Yahoo! Finance | 2 months ago
Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.